1582 related articles for article (PubMed ID: 24661040)
1. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
2. Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study.
Del Giglio M; Gisondi P; Tessari G; Girolomoni G
Dermatology; 2012; 224(1):31-7. PubMed ID: 22456343
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
[TBL] [Abstract][Full Text] [Related]
4. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.
Bardazzi F; Balestri R; Baldi E; Antonucci A; De Tommaso S; Patrizi A
Dermatol Ther; 2010; 23 Suppl 1():S14-9. PubMed ID: 20136916
[TBL] [Abstract][Full Text] [Related]
5. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
6. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
7. Diet and physical exercise in psoriasis: a randomized controlled trial.
Naldi L; Conti A; Cazzaniga S; Patrizi A; Pazzaglia M; Lanzoni A; Veneziano L; Pellacani G;
Br J Dermatol; 2014 Mar; 170(3):634-42. PubMed ID: 24641585
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
9. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
10. Effect of weight loss on the severity of psoriasis: a randomized clinical study.
Jensen P; Zachariae C; Christensen R; Geiker NR; Schaadt BK; Stender S; Hansen PR; Astrup A; Skov L
JAMA Dermatol; 2013 Jul; 149(7):795-801. PubMed ID: 23752669
[TBL] [Abstract][Full Text] [Related]
11. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
16. Body weight increment in patients treated with infliximab for plaque psoriasis.
Florin V; Cottencin AC; Delaporte E; Staumont-Sallé D
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e186-90. PubMed ID: 22621415
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
[TBL] [Abstract][Full Text] [Related]
18. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
Gisondi P; Del Giglio M; Di Francesco V; Zamboni M; Girolomoni G
Am J Clin Nutr; 2008 Nov; 88(5):1242-7. PubMed ID: 18996858
[TBL] [Abstract][Full Text] [Related]
19. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
